HomeInsightsStock Comparison

Kopran Ltd vs Sanofi India Ltd Stock Comparison

Kopran Ltd vs Sanofi India Ltd Stock Comparison

Last Updated on: Aug 18, 2025

Key Highlights

  • The Latest Trading Price of Kopran Ltd is ₹ 157.2 as of 18 Aug 15:30.
  • The p/e ratio of Kopran Ltd changed from 5.2 to 24.5 over 5 quarters. This represents a CAGR of 245.57% The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 7 quarters. This represents a CAGR of -100.00% .
  • The market cap of Kopran Ltd changed from ₹ 109.65 crore to ₹ 1245 crore over 5 quarters. This represents a CAGR of 598.78% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% .
  • The revenue of Kopran Ltd for the Jun '25 is ₹ 137.77 crore as compare to the Mar '25 revenue of ₹ 175.62 crore. This represent the decline of -21.55% The revenue of Sanofi India Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Kopran Ltd for the Jun '25 is ₹ 16.69 crore as compare to the Mar '25 ebitda of ₹ 20.35 crore. This represent the decline of -17.99% The ebitda of Sanofi India Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Kopran Ltd changed from ₹ 2.77 crore to ₹ 7.45 crore over 9 quarters. This represents a CAGR of 55.23% The net profit of Sanofi India Ltd changed from ₹ 190.4 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% .
  • The dividend payout of Kopran Ltd changed from 55.28 % to 53.94 % over 5 quarters. This represents a CAGR of -1.94% The dividend payout of Sanofi India Ltd changed from 175.77 % to 0 % over 11 quarters. This represents a CAGR of -100.00% .

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Kopran Ltd

  • Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises.
  • The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment.
  • It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin.
  • Kopran also makes penicillin-G acylase, an enzyme made through fermentation.
  • It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities.

About Sanofi India Ltd

  • Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
  • The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
  • The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
  • The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
  • It has its own manufacturing facility at Goa.

Kopran Ltd News Hub

News

Kopran to hold AGM

Kopran announced that the 66th Annual General Meeting(AGM) of the company will be held on ...

Read more

31 Jul 2025 09:15

News

Kopran to table results

Kopran will hold a meeting of the Board of Directors of the Company on 29 July 2025. Power...

Read more

19 Jul 2025 10:03

News

Board of Kopran recommends final dividend

Kopran announced that the Board of Directors of the Company at its meeting held on 15 May ...

Read more

15 May 2025 16:01

News

Kopran to hold board meeting

Kopran will hold a meeting of the Board of Directors of the Company on 15 May 2025. Powere...

Read more

07 May 2025 14:37

News

Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly

The United States Food and Drug Administration (USFDA) recently carried out a surveillance...

Read more

28 Apr 2025 15:03

News

Kopran to declare Quarterly Results

Kopran will hold a meeting of the Board of Directors of the Company on 11 February 2025. P...

Read more

05 Feb 2025 12:53

Sanofi India Ltd News Hub

News

Sanofi India announces cessation of senior management personnel

Sanofi India announced that Surabhi Kaul, People Director - SEA&I, will cease to be a Seni...

Read more

14 Aug 2025 09:31

News

Sanofi India to hold board meeting

Sanofi India will hold a meeting of the Board of Directors of the Company on 31 July 2025....

Read more

19 Jul 2025 10:01

News

Sanofi India to hold board meeting

Sanofi India will hold a meeting of the Board of Directors of the Company on 14 May 2025. ...

Read more

10 May 2025 10:52

News

Sanofi India MD Rodolfo Hrosz resigns

The board of directors accepted Hrosz's resignation during a meeting held on 9 April and e...

Read more

11 Apr 2025 11:01

News

Sanofi India to convene AGM

Sanofi India announced that the 69th Annual General Meeting(AGM) of the company will be he...

Read more

19 Mar 2025 12:01

News

Board of Sanofi India recommends final dividend

Sanofi India announced that the Board of Directors of the Company at its meeting held on 2...

Read more

28 Feb 2025 09:13

SWOT Analysis Of Sanofi India Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Kopran Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Sanofi India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Kopran Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Kopran Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Kopran Ltd or Sanofi India Ltd?

Market cap of Kopran Ltd is 759 Cr while Market cap of Sanofi India Ltd is 11,761 Cr

What are the key factors driving the stock performance of Kopran Ltd and Sanofi India Ltd?

The stock performance of Kopran Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kopran Ltd and Sanofi India Ltd?

As of August 18, 2025, the Kopran Ltd stock price is INR ₹157.2. On the other hand, Sanofi India Ltd stock price is INR ₹5107.2.

How do dividend payouts of Kopran Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Kopran Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions